Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
August 1, 2025